Supplemental material
Adopting More Holistic Approaches
Trial Size for Near-Optimal Choice Between Surveillance and Aggressive Treatment: Reconsidering MSLT-II
Charles F. ManskiDepartment of Economics and Institute for Policy Research, Northwestern University, Evanston, IL; Correspondence[email protected]
http://orcid.org/0000-0001-7260-7686
http://orcid.org/0000-0001-7260-7686 & Related Research Data
Completing the Dissection in Melanoma: Increasing Decision Precision.
Source:
Springer Science and Business Media LLC
Sufficient trial size to inform clinical practice.
Source:
Proceedings of the National Academy of Sciences
Minimax regret treatment choice with finite samples
Source:
Elsevier BV
STATISTICAL TREATMENT RULES FOR HETEROGENEOUS POPULATIONS
Source:
The Econometric Society
The Theory of Statistical Decision
Source:
Informa UK Limited
The Other Arbitrary Cutoff
Source:
eScholarship, University of California
Trial Size for Near-Optimal Choice Between Surveillance and Aggressive Treatment: Reconsidering MSLT-II
Source:
Taylor & Francis
The continuing unethical conduct of underpowered clinical trials.
Source:
American Medical Association (AMA)
An economic theory of statistical testing
Source:
The IFS
Moving to a World Beyond “p < 0.05”
Source:
Informa UK Limited
Statistical Decision Theory and Bayesian Analysis
Source:
Springer New York
Treatment Choice With Trial Data: Statistical Decision Theory Should Supplant Hypothesis Testing
Source:
Informa UK Limited
Bayesian Approaches to Randomized Trials
Source:
JSTOR
Trial Size for Near-Optimal Choice Between Surveillance and Aggressive Treatment: Reconsidering MSLT-II
Source:
Taylor & Francis
Linking provided by
